Samuel Goldfarb, MD, is the Director of the Pediatric Cystic Fibrosis Program and CoDirector of the University of Minnesota Cystic Fibrosis Center. He is a Professor of Pediatrics at the University of School of Medicine. Dr. Goldfarb is the holder of the Annalisa Marzotto Endowed Chair in Cystic Fibrosis Care.

A graduate of Tel Aviv University Medical School, Dr. Goldfarb completed his pediatric internship and residency at Bridgeport Hospital, Yale University, CT. He continued his specialty training at the Children's Hospital of Philadelphia with a fellowship in pediatric pulmonology and continued as a faculty member at the Children's Hospital of Philadelphia until February 2021 when he joined the University of Minnesota.

Dr. Goldfarb maintains a special interest in the treatment of children with cystic fibrosis, interstitial lung disease, lung transplantation, early and late pulmonary complications of oncology therapy, and pulmonary involvement of rheumatological disorders.

Dr. Goldfarb serves as the Chair of the American Thoracic Society Special Interest Group "Pulmonary Complications of Childhood Cancer Therapy" participating in the development of standardized care protocols and developing several multi-center clinical studies. He is also a member of the American Thoracic Society, the Rare Diffuse Pediatric Lung Disease Consortium, and the Therapeutic Development Network (TDN) for the Cystic Fibrosis Foundation.

Dr. Goldfarb is an active clinical researcher after a decade of NIH supported research in pediatric lung transplantation he has turned his attention to research in patients with Cystic Fibrosis while continuing his research in patients with pulmonary disease after bone marrow transplants. Dr. Goldfarb began his career as a basic science researcher working to better understand CFTR function and its interaction with chaperone proteins which can enhance abnormal CFTR function. He has continued throughout his career in clinical research and has been part of the TDN research network, most recently becoming the University of Minnesota Pediatric TDN director. Dr. Goldfarb is very active in ongoing research with CFTR modifier medications.